Name
GS3-05 - NSABP B-59/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative BC. (China)
Date & Time
Friday, December 20, 2024
Speakers
Virtual Session Link